Combined large cell neuroendocrine carcinoma : clinical characteristics, prognosis and postoperative management
© The Author(s) 2022. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved..
OBJECTIVES: Combined large cell neuroendocrine carcinoma (C-LCNEC) is pulmonary large cell neuroendocrine carcinoma (LCNEC) mixed with other components, such as adenocarcinoma (AD) and squamous cell carcinoma (SCC). This study aimed to describe the distinct features between C-LCNEC with different components and explore the treatment strategy.
METHODS: We retrospectively collected data of 96 C-LCNEC patients who underwent surgical resection. Propensity score matching was used to balance baseline characteristics of LCNEC combined with AD (LCNEC/AD) and LCNEC combined with SCC (LCNEC/SCC).
RESULTS: In our final cohort, 71 (74%) were LCNEC/AD, while 25 (26%) were LCNEC/SCC. LCNEC/AD was more likely to occur in female, younger adults, with visceral pleural invasion and with driver gene expression. However, there was no significant difference in disease-free survival and overall survival between the 2 groups (before matching: P = 0.79 and P = 0.85; after matching: P = 0.87 and P = 0.48), while adjuvant chemotherapy (P = 0.019 and P = 0.043) was an independent predictor. C-LCNEC patients of stage II or III receiving adjuvant chemotherapy had longer disease-free survival and overall survival (P = 0.054 and P = 0.025), and the benefit of etoposide-based chemotherapy was greater than the other regimens (P = 0.010 and P = 0.030). EGFR and ALK mutations were present in 28% (17/60) and 7% (4/60) of C-LCNEC patients, respectively, and they responded well to targeted therapy.
CONCLUSIONS: LCNEC/AD was the most common type of C-LCNEC, and there were many differences between different combined components. Adjuvant chemotherapy, especially etoposide-based chemotherapy, was a beneficial option for resected C-LCNEC.Subj collection: 152.
| Errataetall: |
CommentIn: Eur J Cardiothorac Surg. 2022 Mar 12;:. - PMID 35277717 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:62 |
|---|---|
| Enthalten in: |
European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery - 62(2022), 2 vom: 11. Juli |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yang, Zhengyu [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
6PLQ3CP4P3 |
|---|
| Anmerkungen: |
Date Completed 01.08.2022 Date Revised 15.09.2022 published: Print CommentIn: Eur J Cardiothorac Surg. 2022 Mar 12;:. - PMID 35277717 Citation Status MEDLINE |
|---|
| doi: |
10.1093/ejcts/ezac069 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM336798512 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM336798512 | ||
| 003 | DE-627 | ||
| 005 | 20231225232948.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/ejcts/ezac069 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1122.xml |
| 035 | |a (DE-627)NLM336798512 | ||
| 035 | |a (NLM)35147672 | ||
| 035 | |a (PII)ezac069 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yang, Zhengyu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Combined large cell neuroendocrine carcinoma |b clinical characteristics, prognosis and postoperative management |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.08.2022 | ||
| 500 | |a Date Revised 15.09.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentIn: Eur J Cardiothorac Surg. 2022 Mar 12;:. - PMID 35277717 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2022. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved. | ||
| 520 | |a OBJECTIVES: Combined large cell neuroendocrine carcinoma (C-LCNEC) is pulmonary large cell neuroendocrine carcinoma (LCNEC) mixed with other components, such as adenocarcinoma (AD) and squamous cell carcinoma (SCC). This study aimed to describe the distinct features between C-LCNEC with different components and explore the treatment strategy | ||
| 520 | |a METHODS: We retrospectively collected data of 96 C-LCNEC patients who underwent surgical resection. Propensity score matching was used to balance baseline characteristics of LCNEC combined with AD (LCNEC/AD) and LCNEC combined with SCC (LCNEC/SCC) | ||
| 520 | |a RESULTS: In our final cohort, 71 (74%) were LCNEC/AD, while 25 (26%) were LCNEC/SCC. LCNEC/AD was more likely to occur in female, younger adults, with visceral pleural invasion and with driver gene expression. However, there was no significant difference in disease-free survival and overall survival between the 2 groups (before matching: P = 0.79 and P = 0.85; after matching: P = 0.87 and P = 0.48), while adjuvant chemotherapy (P = 0.019 and P = 0.043) was an independent predictor. C-LCNEC patients of stage II or III receiving adjuvant chemotherapy had longer disease-free survival and overall survival (P = 0.054 and P = 0.025), and the benefit of etoposide-based chemotherapy was greater than the other regimens (P = 0.010 and P = 0.030). EGFR and ALK mutations were present in 28% (17/60) and 7% (4/60) of C-LCNEC patients, respectively, and they responded well to targeted therapy | ||
| 520 | |a CONCLUSIONS: LCNEC/AD was the most common type of C-LCNEC, and there were many differences between different combined components. Adjuvant chemotherapy, especially etoposide-based chemotherapy, was a beneficial option for resected C-LCNEC.Subj collection: 152 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Adjuvant chemotherapy | |
| 650 | 4 | |a Carcinoembryonic antigen | |
| 650 | 4 | |a Combined large cell neuroendocrine carcinoma | |
| 650 | 4 | |a Survival analysis | |
| 650 | 7 | |a Etoposide |2 NLM | |
| 650 | 7 | |a 6PLQ3CP4P3 |2 NLM | |
| 700 | 1 | |a Wang, Yanan |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Ya |e verfasserin |4 aut | |
| 700 | 1 | |a Qian, Fangfei |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Yanwei |e verfasserin |4 aut | |
| 700 | 1 | |a Hu, Minjuan |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Wei |e verfasserin |4 aut | |
| 700 | 1 | |a Han, Baohui |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery |d 1996 |g 62(2022), 2 vom: 11. Juli |w (DE-627)NLM012606200 |x 1873-734X |7 nnns |
| 773 | 1 | 8 | |g volume:62 |g year:2022 |g number:2 |g day:11 |g month:07 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/ejcts/ezac069 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 62 |j 2022 |e 2 |b 11 |c 07 | ||